HighTower Advisors LLC Has $248,000 Stock Position in Haemonetics Co. (NYSE:HAE)

HighTower Advisors LLC cut its holdings in shares of Haemonetics Co. (NYSE:HAE) by 15.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,109 shares of the medical instruments supplier’s stock after selling 556 shares during the quarter. HighTower Advisors LLC’s holdings in Haemonetics were worth $248,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of HAE. Holocene Advisors LP acquired a new position in Haemonetics during the 3rd quarter worth approximately $5,419,000. Atom Investors LP acquired a new position in shares of Haemonetics during the third quarter worth $1,571,000. Paloma Partners Management Co bought a new position in shares of Haemonetics in the 3rd quarter valued at $623,000. Captrust Financial Advisors boosted its holdings in shares of Haemonetics by 30.1% during the 3rd quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier’s stock valued at $341,000 after acquiring an additional 982 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in Haemonetics by 174.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after acquiring an additional 10,774 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Up 0.3 %

Shares of NYSE:HAE opened at $77.41 on Wednesday. Haemonetics Co. has a 1 year low of $70.25 and a 1 year high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The business’s 50-day moving average is $81.42 and its 200-day moving average is $81.17. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of 32.12, a P/E/G ratio of 1.29 and a beta of 0.38.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period last year, the business posted $0.99 EPS. Equities research analysts predict that Haemonetics Co. will post 4.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HAE shares. CL King assumed coverage on shares of Haemonetics in a report on Friday, September 13th. They issued a “buy” rating and a $116.00 price objective for the company. Bank of America started coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $112.00 target price on shares of Haemonetics in a research report on Tuesday, December 3rd. Barrington Research reiterated an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a research report on Wednesday, December 4th. Finally, Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a research note on Friday, November 8th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.